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One in every 700 children is affected by pediatric cancer and 5 to 10% of all cancers are 
attributable to inherited genetic mutations.  A subset of these cancers, referred to as Cancer 
Predisposition Syndromes (CPS), result from pathogenic mutations that are known to increase 
cancer risk.  Identification of these specific mutations in these patients facilitates treatment, 
however, many of these patients may not be identified or referred to a genetics clinic. Clinicians 
at UPMC Children’s Hospital of Pittsburgh developed a screening tool to identify patients that 
might have cancer predisposition syndromes and conducted a retrospective chart review of their 
patients from 2012-2017.  Based on their study, an estimated 40% of pediatric cancer patients who 
met the criteria for a possible CPS were underdiagnosed.  These results highlighted the need for a 
comprehensive standardized screening tool and referral program to a cancer predisposition 
clinic.  I compared the demographics, referral patterns, and number of patients who tested positive 
for a genetic mutation associated with a cancer predisposition syndrome before and after the 
implementation of a cancer predisposition clinic. In general, the racial/ethnic composition of the 
two studies were similar, and also similar to the composition of western Pennsylvania.  However, 
significantly more males than females were seen by the clinic; pediatric cancer rates and cancer 
predisposition syndromes were similar.  The reason for this discrepancy is unclear, but similar 
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results were reported by the Boston Children’s Hospital.  Finally, the number of patients seen in 
the Cancer Predisposition Clinic increased a mean 26% per year compared to the number of 
patients that met criteria for referral in the retrospective study, indicating the screening tool and 
referral program is successful. Increasing access to the cancer predisposition clinic, enables better 
management of pediatric cancer patients, potentially increasing longevity, and decreasing 
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1.0   INTRODUCTION 
Cancer is defined as a group of diseases in which abnormal cells divide without control 
and can invade nearby tissues.(National Cancer Institute,2015) Several types of risk factors affect 
the development of cancer including genetics, environmental factors, epigenetic changes to DNA.  
(Papaemmanuil et al., 2009) According to the World Health Organization (WHO) research, 35% 
of deaths due to cancer worldwide are due to potentially modifable risk factors some of which 
include smoking, diet, ultraviolet radiation, physical activty, infections, etc. (Lewandowska, 
Rudzki, Rudzki, Lewandowski, & Laskowska, 2019) 
Currently, 80-90% of malignant tumors are caused by external environmental factors. 
(Lewandowska et al., 2019) External factors can contribute to epigenetic change, for example 
DNA methylation, the cell resulting in either cell malfunction ror cell death. Both enivronmental 
and epigenetic factors can affect numerous cells resulting in a accumulation of changes. When 
these changes occur along with genetic changes this creates an environment of genetic instability 
and disrupts cell function resulting in cancer. (Herceg, 2007) Although environmental factors, 
epigenetics, and genetic predisposition are all play a key role in the development of cancer, cancer 
is genetic.  
Incidence of cancer: --In 2017, 1,701,315 new cases of cancer were diagnosed and between 
2013-2017, the cancer incidence rate was 442.2 per 100,000 men and women per year (Centers for 
Disease Control and Prevention, 2019).   Of the 1.7 million total cases, 15,013 (or 0.8%) were 
individuals <20 years of age.  Cancer among individuals < 20yo are defined as pediatric cases of 
cancer.  In Pennsylvania, the total number of new cases of cancer in the state in 2017 was 77,817 
of whom 574 (or 0.7%) were <20 years of age.  (Pennsylvania Department of Health, 2021)   Thus, 
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the frequency of pediatric cancer in PA is similar to that in the USA.  Among the pediatric cancer 
cases in PA, the frequency is slightly higher in males (51%) than females (49%).  In addition, 
among patients under <20yo, 449 (78%) cases were white and 54 (9%) were black. (Pennsylvania 
Department of Health, 2021)  
Cancer mortality rates. -- Cancer is the second leading cause of death in the United States; 
In 2019, 599,601 people died from cancer. (CDC, 2021) The cancer mortality rate was 158.3 per 
100,000 men and women per year and the rate of mortality due to cancer is higher in men than 
women. (National Cancer Institute, 2020) Among children (aged 0-19 years old), cancer is the 
leading cause of death in the United States.  In Pennsylvania, 28,318 people died of cancer in 2017 
of whom, 53 (or 0.18%) were individuals <20 years old. Of these 53 pediatric cancer deaths, 31 
(58%) were females and 22 (42%) were males. The majority of these pediatric cancer deaths were 
white (37 or 70%) with 9 (17%) Hispanics, 6 (11%) blacks, and 1 (2%) Asian/Pacific Islander. 
(Pennsylvania Department of Health, 2021) 
Types of pediatric cancer:-- Two of the most common types of pediatric cancer are acute 
leukemia and central nervous system tumors. The two types of acute leukemias [Acute 
Lymphoblastic Leukemia (ALL) and Acute Myelogenous Leukemia (AML)] account for 25% of 
newly diagnosed tumors in children under the age of 15. Of the patients diagnosed with leukemia 
75% are ALL and 20% are AML. (Hastings, Torkildson, Agrawal, & Hastings, 2012)The overall 
incidence of pediatric ALL from 2001-2014 was 34.0 cases per 1,000,000 among all ethnic groups. 
(Siegel et al., 2017) Data provided from the United States Cancer Statistics Data Set reported the 
highest rate of ALL is among Hispanic males aged 1-4 years. Furthermore, the highest incidence 
rate of ALL is in the west region of the United States (38.5 per 1,000,000 people), whereas the 
second highest region was in the northeast with an incidence rate of 34.8 per 1,000,000 people. 
The risk factors contributing to the high prevalence in the Hispanic population are unknown. Some 
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potential risk factors discussed were genetic susceptibility, high rate of environmental exposures 
including household chemicals, and obesity. (CDC, 1997) 
Hastings et al. (2012) proposed that most of leukemia cases result from somatic genetic 
alteration, instead of inherited genetic predisposition.  However, several studies have reported 
genetic variants that are associated with increased risk of ALL.   Papaemmanuil et al. (2009) 
analyzed genotype data that was collected as part of several clinical trials. Some of the participants 
in these clinical trials had ALL.  The investigators conducted a genome-wide association (GWA) 
study using genotype data on patients with ALL and controls.   They identified 10 genetic variants 
(or single nucleotide variants, SNVs) that were more frequent in patients with ALL than in the 
control patients. In addition, Treviño et al. (2009) identified 18 SNVs whose allele frequency 
differed between pediatric ALL patients and controls. They reported that these 18 SNVs influenced 
an individual’s susceptibility to developing ALL. These reports identified variants that should be 
tested for a predisposition to inherited ALL. 
Central nervous system (CNS) tumors are the second most common type of cancer, but the 
most common type of solid tumor in children, and account for 20% of all pediatric malignancies 
(Hastings et al., 2012) Based on Surveillance, Epidemiology, and End Results Program (SEER) 
data, the incidence rate of brain and other CNS tumors is 5.67 per 100,000 persons per year (Udaka 
& Packer, 2018). The most common type of brain tumor is the medulloblastoma and accounts for 
20% of pediatric brain tumors under the age of 10. Between 250 and 500 children are diagnosed 
with medulloblastomas each year.(Medulloblastoma-Childhood:Statistics,2020) The NCDB 
1998-2011 showed that in patients 0-19 diagnosed with a medulloblastoma, 62.9% were males and 
37.1% were females, 81.3% were white, 10.7% black, 8% unknown(Dressler, Dolecek, Liu, & 
Villano, 2017).  
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1.1 CANCER GENETICS 
Cancer genetics has become increasingly integrated into the field of modern oncology, in 
part because inherited genetic mutations contribute to the development of 5 to 10% of all cancers. 
(National Cancer Institute,2020) A subset of these cancers, cancer predisposition syndromes 
(CPS), result from a pathogenic germline mutation in tumor suppressor genes, which confers an 
increased risk in cancer. (Garber, 2005) Although individuals with genetic predisposition comprise 
a small portion of the overall cancer patient population, successful implementation of cancer 
surveillance and prevention programs may significantly decrease this number of cases. By 
identifying these cancer predisposition patients, physicians would be able to screen other at-risk 
family members for the specific mutation. If this mutation is detected in a family member, an 
individualized preventative cancer surveillance plan could be implemented. Cancer screening and 
prevention program could also decrease the cancer mortality rate. For example, in the 1950s, the 
mortality rate for cervical cancer in the United State was 12 in every 100,000 women. In 2015, 
after implementation of Pap smears tests, the mortality rate was 2 in every 100,00 women. (Pinsky, 
2015) Thus, the mortality rate of cervical cancer decreased 60%. between 1950 and 2015. 
Although the current estimate of pediatric cancers associated with cancer predispositions 
syndromes is 5-10% of all pediatric cancers, this frequency may be higher due to underdiagnosis 
in pediatric populations. For example, an estimated 181,000 childhood cancers will not be 
diagnosed in 2020 as part of a cancer predisposition syndrome. (ACCO, 2021) Thus, the need for 
improvements in referral patterns and standard of care for individuals with pediatric cancers 
associated with cancer predisposition syndromes is evident. 
Cancer genetics may be approached from the identification of cancerous cells which lead 
to genetic testing or vice versa where patients are identified with a cancer predisposition syndrome 
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that leads to preventative cancer screening. Li-Fraumeni Syndrome (LFS) is an aggressive cancer 
predisposition syndrome caused by a mutation in the TP53 gene. This syndrome can cause 
numerous different tumors types including brain tumors, hematologic malignances, and soft tissue 
sarcomas.(Kratz et al., 2017)  In 2016, the American Association for Cancer Research held a 
meeting to discuss LFS and determine the recommended guidelines for surveillance for both 
pediatric and adult patients. These patient populations should follow the screening guidelines due 
to lifelong cancer risk.(Kratz et al., 2017) 
1.2 CANCER PREDISPOSITION SCREENING TOOLS 
 To mitigate this issue of under diagnosis of Cancer Predisposition Syndromes, the 
American Association for Cancer Research held a workshop in 2016 with the primary objective to 
establish guidelines for surveillance of common pediatric cancer predisposition syndromes. 
(AACR, 2017) Health professionals from different backgrounds worked together to develop a 
standardized screening tool to identify patients that are at risk for a CPS.  These patients would 
then be referred for genetic counseling or testing. (Jongmans et al., 2016) After a review of 
literature, these practitioners developed a tool with five criteria to identify patients at high risk for 
genetic susceptibility to a cancer predisposition syndrome. These five criteria (Table 1) represent 





Table 1 Five criteria used to identify a Cancer Predisposition Syndrome (CPS) 
1. Family history 
2. Bilateral, multifocal, or multiple cancers 
3. Earlier age at diagnosis that sporadic tumors of the same type 
4. Physical Findings suggestive of a Cancer Predisposition Syndrome 
5. Occurrence of specific tumor type that frequently occurs in the context of genetic 
predisposition. 
Brodeur et al. (2017) 
1.3 UPMC Retrospective Study to Analyze Referral Rates 
1.3.1  Development of Screening Tool  
In 2017, the Hematology/Oncology Department at UPMC Children’s Hospital of 
Pittsburgh developed a screening tool to identify patients that met criteria for at least one of the 
six questions on the tool. The complete screening tool is listed under Appendix A. The team created 
the screening tool based off of screening tools used at other institutions and articles on screening 
tools that were found through reviewing the literature. The six criteria questions in the tool are 
based upon the five measures used to classify a cancer predisposition syndrome. One additional 
question was added (#4) which states, “Does the child have one of the following inherited 
conditions?”. There are 37 at-risk genetic conditions included for this question.(Amodei, 2017) 
Of the articles reviewed, there was an article in The European Journal of Medicine, that 
discussed an easy-to-use selection tool for patients at high risk for a genetic predisposition 
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syndrome created by a group of physicians in the Netherlands. They created their tool based upon 
the five characteristics of pediatric cancer predisposition syndromes.(Jongmans et al., 2016) These 
additional tools reviewed by the hematology/oncology team are listed in the references. (Postema 
et al., 2017) 
1.3.2  Retrospective Study Data Collection 
          After developing a tool, the physicians and medical students in Hematology/Oncology 
Department of Children’s Hospital of Pittsburgh conducted a small study to analyze the referral 
rate of individuals with pediatric cancer predisposition syndromes in their clinic to either genetics 
or cancer predisposition clinics. They conducted a retrospective chart review of pediatric patients 
who were seen in the past five years (2012-2017) and were identified based on ICD10 codes for 
congenital abnormalities, pediatric malignancies/tumors associated with cancer predisposition 
syndromes. They then used the screening tool to classify patients into one of three categories: (1) 
patients referred for genetic evaluation, (2) patients who met criteria for referral but were not 
referred, and (3) patients who did not meet criteria for referral. (Amodei, 2017) 
1.3.3 Results of Retrospective Study  
A total of 562 patients were identified in the retrospective study who met the criteria of a 
patient identified with a congenital abnormality or pediatric malignancy/tumor associated with 
cancer predisposition syndromes (Figure 1).  
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Figure 1 Retrospective Study Results 
 
As displayed in Figure 1, of the total of 562 patients, 280 (50% of 562) patients met the 
criteria for referral to Cancer Predisposition Clinic.  Of the 280 patients, 56 (20% of 280) were 
referred to Genetics/Cancer Predisposition Clinic.  Finally, 30/56 patients (54%) tested positive 
for genetic mutation associated with a known cancer predisposition risk. (Amodei et al., 2017). 
In summary, the results of this retrospective chart review showed that 50% of patients met 
the criteria for referral for follow-up genetic testing.  These results confirmed the need for a 
standardized screening tool to identify patients with suspected cancer predisposition syndromes. 
Furthermore, 20% of patients who met the criteria were referred for followup genetic testing of 
whom 54% received a genetic diagnosis. Therefore, based on this retrospective study, and 
estimated 44% of patients who met the criteria for referral were underdiagnosed because they were 
not referred (54% of 80% of patients who were not referred).   Thus, an estimated ~20% of patients 
overall were underdiagnosed and did not receive the potential benefits for care and identification 
 9 
of other at-risk family members.  This result highlights the critical need for a comprehensive, 
standardized referral program.  Based on the results of this study, a multidisciplinary Cancer 
Predisposition Clinic and referral program were developed.  (Amodei et al., 2017).   
1.4 Implementation of the Cancer Predisposition Clinic 
In 2017, the hematology/oncology department at UPMC Children’s Hospital of Pittsburgh 
established a pediatric cancer predisposition program. This program is currently implemented in 
an outpatient setting to help families understand hereditary factors that play a role in childhood 
cancer. The goal of this multidisciplinary clinic is to improve the overall care for children with a 
genetic risk factor of cancer susceptibility. This clinic comprises several services including 
oncology physicians, nurses, child life specialists, therapists, and a certified genetic counselor. As 
part of the multidisciplinary team, a genetic counselor is involved in educating the families about 
genetic risk factors and future surveillance of predisposition syndromes. The information that is 
being documented includes, initial diagnosis, confirmed diagnosis and the ICD10 code used to 
classify the malignancy. 
Both the screening tool and the referral process currently being used are based on (1) results 
from retrospective study and (2) methods being used by other centers that have a cancer 
predisposition program. 
1.0  Gaps in knowledge 
The usefulness of the Cancer Predisposition Program at UPMC Children’s hospital and the 
screening tool has not been assessed.  A comparison of the proportions of pediatric patients who 
were diagnosed with hereditary cancers in the retrospective study and after implementation of the 
intervention program is not known.  In addition, the demographics of the patient population for 
the retrospective study or from the current Cancer Predisposition Program have not been assessed.  
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This information would indicate if specific subgroups of the population are being underserved and 
indicate that additional outreach should be initiated.  Finally, the relative frequency of hereditary 
cancers that are being identified has not been assessed.   
To fill in these gaps in knowledge, I conducted a study with the following specific aims. 
1.5   Specific Aims 
 Specific Aim 1.  
Describe demographic characteristics of the retrospective and predisposition clinic study 
populations., using from data obtained from hospital records. 
 Specific Aim 2 
Assess the changes in the screening tool (addition of tumor types and inherited conditions) 
between the retrospective study and predisposition clinic populations. 
 Specific Aim 3 
Assess possible differences between the Retrospective Study and the Genetic 
Predisposition Clinic patient populations. 
a.  Assess whether any demographic characteristics differed between the two patient 
populations 





2.0 Methods and Data 
I compared results from two different cohorts: (1) 562 patients from the retrospective study 
(from 2012-2017) conducted by the hematology department at CHP and (2) 216 patients seen in 
the Cancer Predisposition Clinic at CHP from 2017-2020. I completed a review of the 216 patients 
from the Cancer Predisposition Clinic to have the same data collected in the retrospective study.  
2.1 Retrospective Study Population 
A total of 562 patients were identified in the retrospective study who met the criteria of a 
patient identified with a congenital abnormality or pediatric malignancy/tumor associated with 
cancer predisposition syndromes. This information was collected through a review of each 
patient's electronic medical records at CHP that came to the Hematology/Oncology clinic between 
2012-2017. The initial data collection was completed by a fellow and medical student in the 
Hematology/Oncology Department.   
Data on the demographics of the 280 patients that met the criteria for referral to Genetics 
and/or a Cancer Predisposition clinic were collected from electronic medical records at CHP. 
These data included age, sex, ethnicity, geographical location (zip code).  
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2.2 Predisposition Clinic Population 
The Cancer Predisposition Clinic was implemented in 2017 and 216 patients were seen in 
the clinic through December 2020.  Demographic information (including age, sex, ethnicity, and 
geographical location (zip code) for these patients were obtained from electronic medical records 
at CHP. 
In addition, given the advancements in cancer genetics and the identification of new tumor 
types and genetic mutations and conditions associated with cancer predisposition syndromes, I 
also determined whether the specific tumor types had been added (or subtracted) from the 
screening tool used in the retrospective study versus the one use on the predisposition clinic 
population. 
2.3 Methods 
Descriptive data are presented as n (%). Chi-square tests were used to assess possible 
differences in demographics or genetic diagnoses between the two patient populations. 
I collected the zip code for each patient from the electronic medical records at UMPC 
Children’s Hospital of Pittsburgh. Zip codes were collected and grouped together by state. Two 
custom maps were made of patient zip codes grouped together by county and www.mapchart.net 
was used to generate visual representation to show the distribution of patient zip codes by county 
in Pennsylvania.  
I reviewed the screening tools used in the retrospective study and the predisposition clinic 
and identified the new tumor types that were added. 
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3.0 Results 
3.1 Changes in the screening tool 
The screening tool developed for the retrospective study in 2017 had 34 tumor types.  Since 
that time, and in the three years that the cancer predisposition clinic has been operating, an 
additional 4 tumor types have been added to the screening tool utilized by the cancer predisposition 
clinic (Appendix 1). These 2 tumor types were low hypodiploid acute lymphoblastic leukemia, 
and myelodysplastic syndrome. All other components of the tools used for the retrospective study 
and in the current cancer predisposition clinic were the same.  
3.2 Demographics of the retrospective and current populations 
           As part of the Retrospective Study, a total of 282 patients (who would have met criteria for 
referral to a Genetic Predisposition Clinic) were identified over a period of 5 years (from 2012 and 
2017), approximately 56 children/year.  As can be seen in Table 3, the majority (62%) of patients 
who met the criteria for referral in the retrospective study were female. Almost all (91%) of 
patients were Caucasian, 6.9% were African American, less than 1% were Guam, less than 1% 
were Asian/Pacific Islander, and less than 2% were unknown or declined to provide their ethnicity. 
Most patients resided in Pennsylvania (96%), less than 1% were from Ohio, 1.2% were from West 
Virginia, and 1.4% were unknown. 
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Table 2 Demographics of Retrospective and Predisposition Clinic 
 Retrospective 
      Study 
 Predisposition Clinic 
Total number of Patients 280 216 
GENDER NUMBER OF 
PATIENTS (%) 
NUMBER OF PATIENTS (%) 
MALE 106 (38%) 121 (56%) 
FEMALE 174 (62%)   95 (44%) 
RACE  
WHITE 255 (91%) 194 (90%) 
AFRICAN AMERICAN   19 (6.9%)   11 (5%) 
GUAM     1 (0.35%)         - 
INDIAN (ASIA)     1 (0.35%)         - 
UNKNOWN     2 (0.7%)     8 (4%) 
DECLINED     2 (0.7%)     3 (1%) 
ZIP CODE  
PENNSYLVANIA 271 (96%) 211 (98%) 
OHIO     2 (0.7%)     2 (1%) 
WEST VIRGINIA     3 (1.2%)     3 (1%) 
UNKNOWN     4 (1.4%)         - 
 
In the three-year period between December 2017 and December 2020, the Genetic 
Predisposition Clinic treated 216 children, for a mean of 72 children per year.  This change is a 
26% per year increase in the number of children who met the criteria for referral compared to the 
retrospective study (from 2012-2017).  Except that the proportion of males seen in the Clinic Study 
was higher than in the Retrospective Study patient population, the demographics of the cancer 
predisposition clinic patients were similar to those from the Retrospective Study.  For example, 
most of the patients were Caucasian (90%), 5% were African American, 4% are unknown, and 1% 
declined to provide their ethnicity. In addition, almost all of the patients resided in Pennsylvania 
(98%).  The proportion of males seen in the Clinic study was 50% higher than the number who 
met the requirements for referral in the Retrospective Study, 56% versus 38%, retrospectively.  
This difference was highly significant (X21df = 16.2036, p = 0.000057, see Appendix C Table 6).   
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3.2.1 Geographic location by County 
In addition to investigating which states the Cancer Predisposition Clinic patients resided 
in, Pennsylvania counties patients like in based on zip codes were investigated using heat maps.  
The UPMC Children’s Hospital is located in Allegheny County in Pittsburgh, PA.  As can be seen, 
the largest number of patients resided in Allegheny county.    In the Retrospective Study, patients 
who met the criteria for referral came from a total of 19 counties, although 13 counties had >5 
patients.   In the Genetic Predisposition Clinic patient population, patients came from a total of 30 
counties, and 14 counties had >5 patients.  For details on the specific numbers of patients from 
each county, see Table 5 in Appendix B.  
 
 
Figure 2 Retrospective County Numbers 
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Figure 3 Predisposition Clinic County Numbers 
3.3 Identification of Genetic Mutations for Specific Cancer Predisposition Syndromes 
Since the Cancer Predisposition Clinic was implemented in 2017, 216 patients have been 
seen in the clinic through December 2020. Of the 216 patients, a specific causal mutation has been 
identified in 84 patients (39%).   A causal mutation was not identified for the remaining 61% of 
the patients.   Among these patients, testing did not reveal any potentially causal variants for 86 
patients.  For 19 patients, testing identified a variant, but the effect of the variant was unknown, 
that is, a variant of unknown significance (VUS) The remaining 27 patients did not undergo testing 
for a variety of reasons.    
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Table 3 Testing Results for Clinic Patients (n=216) from 2017 to 2020 
TESTING RESULTS NUMBER OF 
PATIENTS n (%) 
POSITIVE TEST 84 (39%) 
NEGATIVE TEST 86 (40%) 
VARIANTS OF UNKNOWN SIGNIFICANCE (VUS) 19 (9%) 
OTHER 27 (12%) 
 I next assessed whether the number of patients who received genetic diagnosis differed 
between the two patient populations (Table 4).  Because information regarding VUS and Other 
outcomes was not available for the Retrospective Study, I only analyzed the number of positive 
and negative tests.  
 
Table 4 Analysis of Genetic Testing in Two Patient Populations 
 Retrospective (n)  Predisposition Clinic (n) 
Positive 30  84  
Negative 26  86  
 
As can be seen, the proportion of positive genetic diagnoses in the Retrospective Study 
(53.5%) was similar to that in the Cancer Predisposition Clinic (49.5%) and the difference in these 
proportions was not statistically significant ( X21df,  p = 0.69).  
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4.0 Discussion  
Early detection and positive identification of genetic mutations in pediatric cancer patients 
will enable better management of their condition and potentially increase longevity, as well as 
facilitate early identification of family members at risk.  Implementing an intervention to identify 
and refer pediatric cancer patients will facilitate this process.  In early 2017, physicians at UPMC 
Children’s Hospital of Pittsburgh conducted a retrospective chart review of pediatric cancer 
patients with hereditary cancers.  The results of this chart review highlighted the need for a 
comprehensive, standardized referral program and showed that and estimated 40% of patients with 
hereditary cancers remained underdiagnosed.  Thus, in 2017, the hematology/oncology department 
at UPMC Children’s Hospital of Pittsburgh established a pediatric cancer predisposition program 
in an outpatient setting.  
As described in the Results, the number of patients seen in the pediatric Cancer 
Predisposition Clinic increased a mean 26% per year compared to the number of patients that met 
the criteria for referral in the retrospective study. This increase, in part, may be due to the addition 
of tumor types to the screening tool. Given the advancements in cancer genetics and the 
identification of new tumor types and genetic mutations and conditions associated with cancer 
predisposition syndromes, the screening tool will continue to be updated.   In particular, two of the 
most common childhood tumor types, ALL and AML, were added to the screening tool, after 
several reports in the literature identified specific variants that increased susceptibility for 
development of ALL and AML.  
In addition, this 26% increase is likely an under-representation of the effect of using the 
screening tool to identify patients for referral.   In the past three years, the number of patients that 
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were seen in the Predisposition Clinic steadily increased. In 2018, 31 patients were seen. In 2019, 
85 patients were seen, an increase of 274%. In 2020, 94 patients were seen, however, this relatively 
lower increase may be a consequence of the COVID-19 pandemic.  In support of this latter 
hypothesis, over 27 patients have been scheduled during the first quarter of 2021, indicating a 
possible backlog of patients.  Thus, the number of patients in 2021 is likely to exceed the number 
of patients in 2020.   
Finally, the increase in the number of patients may be attributable, in part, to increasing 
awareness of the pediatric Cancer Predisposition Clinic by health care professionals and the public 
and the expansion of the UPMC system.  Support for this hypothesis is based on the observation 
that patients seen by the Clinic reside in 30 counties, whereas the patients in the retrospective study 
resided in 19 counties (Figure 2 and 3).  However, assessment of this latter hypothesis is beyond 
the scope of this essay. 
As described in the Introduction, all cancer is genetic (due to changes in genes and gene 
expression), although the causes of these changes may be due to endogenous and exogenous 
environmental factors.(Lewandowska et al., 2019) Also, most cancers are due to sporadic 
mutations and most of the genes and variants that contribute to the development of different 
cancers are unknown. Therefore, as additional tumor types are added to the screening tool, and 
more patients are referred to the Cancer Predisposition Clinic, the proportion of positive genetic 
diagnoses will decrease, and the proportion of negative results and variants of unknown 
significance will increase.  This outcome is observed in Table 4, the proportion of positive results 
decreased (39%) in the Cancer Predisposition Clinic and the number of VUS increased (to 9%).  
Some of these VUS may be recategorized as pathogenic (i.e., a positive test result), whereas other 
will be classified as nonpathogenic (a negative test result).  For example, based on a study of 4644 
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individuals carrying 2383 BRCA1/2 variants, bioinformatic analyses indicated that 22 VUS had 
odds >10:1 in favor of pathogenicity. (Li et al., 2020) Thus, in this small study, only ~1% of VUS 
may be pathogenic.  The remainder will be reclassified as non-pathogenic (negative test results) 
or remain unknown. St. Jude Children’s Research Hospital developed PeCan-PIE (Pediatric 
Cancer Variant Pathogenicity Exchange Program) a cloud based variant classification and 
interpretation service following ACMG Guidelines. The portal contains a repository of expert-
reviewed germline mutations that may predispose individuals to cancer. Researchers and 
physicians have access to this portal. Thus, they are able to use this site to determine VUS from 
their patients and compare them to the information in the portal and determine variants that may 
cause a cancer predisposition syndrome. (St. Jude Children’s Research Hospital, 2020)   
The racial/ethnic composition of the patient population in the retrospective study and the 
Clinic were similar.  Most of the patients self-identified as white (91% and 90% in the retrospective 
study and clinic, respectively).  Slightly more patients from the retrospective study (6.9%) versus 
the clinic (4%?) identified as African American. In PA, 81.6% of the population identifies as 
Caucasian and 12% of the population is African American.  Furthermore, among all pediatric 
cancer cases in PA, 78% are white and 9% were black. (Pennsylvania Department of Health, 2021)   
Thus, the clinic is seeing more whites and fewer blacks. Although the numbers are small, this 
potential disparity may be due to differential rates of genetic predisposition syndromes between 
blacks and whites, however I think this is unlikely given the overall prevalence of pediatric cancer 
in PA. This potential disparity may also be due to several factors that are known to affect use of 
healthcare among under-represented populations such as lack of insurance, transportation, and 
access, as well as distrust of the medical establishment; all of which may lead to a longer time to 
diagnosis.  Because the numbers are small, more research needs to be done.   
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The proportion of males seen in the Clinic study was 50% higher than the number who met 
the requirements for referral in the Retrospective Study, 57% versus 38%, retrospectively. Siegal 
and colleagues reported that in adults, between 2009-2013, the incidence of cancer was ~20% 
higher in men than in women and the mortality rate was 40% higher in men than women in the 
United States. (Siegel et al., 2018) The PA Cancer Statistic Board reported that the incidence rate 
of cancer in persons <20 years was higher in males (0.8%) than females (0.7%) from 2012-2017. 
(Pennsylvania Department of Health, 2021) Thus, in Pennsylvania, males <20 years old, have 
higher risks of developing cancer than females. However, the magnitude of the difference in risk 
is less than the that observed in the clinic.  Similarly, the reason for the large differences in the 
proportion of males and females in the retrospective study versus the clinic study is unclear.  
However, these values for the Retrospective Study and the Clinic Study are based on different 
baselines.  The Retrospective Study was a chart review that identified all children who met the 
criteria for referral. In contrast, the clinic study represents all children who met the criteria, were 
referred, and attended the clinic.  I have been unable to obtain information regarding the number 
of patients who were referred.    
Boston Children’s Hospital (BCH) has also implemented a pediatric cancer genetic risk 
program similar to the clinic at Children’s Hospital of Pittsburgh. Their program provides cancer 
risk assessment, comprehensive recommendations for managing cancer risk in children, and 
psychosocial support for both patients and families. (Groves et al., 2019) In Massachusetts, the 
total number of new cases of cancer in the state in 2017 was 38,079 of whom 311 (or 0.8%) were 
<20 years of age. (Massachusetts Cancer Registry, 2020)   Thus, the frequency of pediatric cancer 
in MA is similar to that in PA in the USA.  Among the pediatric cancer cases, the frequency is 
slightly higher in males (57%) than females (43%), again similar to the frequencies in 
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Pennsylvania (58% vs. 42% respectively).  In addition, 64% of pediatric cancer cases were white 
and 6% were black; the frequencies of pediatric cancer cases in Pennsylvania, is slightly higher 
among whites (78%), but similar among blacks (9%).  BCH investigators conducted a study on 
their patient population to determine the prevalence and scope of medical and psychosocial needs. 
The investigators reported that the frequency of males in their population was higher than females 
(58.9 versus 41.1%, respectively).  In addition, they reported that more whites than blacks were 
seen: whites 80.8%; African Americans 17.8%; and other 1.4%)(Groves et al., 2019), These results 
are similar to the results from the Cancer Predisposition Clinic. Again, the reasons for the 
substantially higher frequency of males than females, are unclear. 
 
In summary, results of my study demonstrate the usefulness of a screening tool to refer pediatric 
patients to a multidisciplinary cancer predisposition clinic. Development of a standardized 
screening tool and referral process have increased the number of pediatric patients who are seen 
by the clinic.  Given the advances in genetic knowledge and treatment of syndromes, identification 
of specific mutations for a cancer predisposition syndrome will enable earlier detection of the 
syndrome and better long-term management of the child’s and/or family member’s health. 
However, several disparities were noted.  First, a higher proportion of males are referred 
to the clinic and a lower proportion of blacks are referred, especially in comparison to the reported 
frequency of pediatric cancers in these groups in Pennsylvania.  Intriguingly, similar results were 
seen in the BCH study.  Additional studies to confirm these disparities and to determine the causes 




This study has several limitations. First, almost all of the patients are from Western 
Pennsylvania. Although the BCH program reported demographics among patients seen in their 
clinic, that is, higher proportion of males and lower proportions of blacks than expected, these 
results may not be representative of the whole United States or their respective communities. 
Second, most of the information regarding most of variants associated with cancer susceptibility 
has been derived from white populations. This bias is likely to result in an underrepresentation of 
positive test mutations in other ethnicities. e screening tools developed by BCH and UPMC (which 
are very similar) were used to analyze patients from other geographical regions and/or comprised 
of predominantly non-white populations.    
A second limitation was the inability to obtain the total number of patients who were 
referred to the predisposition clinic. This number would be the equivalent to the 562 patients in 
the retrospective study.  In other words, the proportions of males versus females, ethnic/racial 
composition, and geographic location in the retrospective study may not be equivalent between 
the two studies, especially if the dropout rate differed by sex, race/ethnicity, or location.  
Furthermore, the baselines differed between the retrospective study and the clinic with regards to 
identification of mutations.  The retrospective study contained a small subset (31%) of the patients 
who met the criteria referral, whereas in the clinic study, more patients who met the screening 
criteria were assumed to be referred.  If the patients in the retrospective study who were referred 
to the clinic represented a biased subset of the at-risk population, the frequency of identified 
mutations would differ. For example, if only patients with a strong family history of risk were 
referred, the probability of identifying a risk allele may be increased. 
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Appendix A Cancer Predisposition Clinic Screening Tool 
Patient name:                                                                                                    Patient date of birth: 
 
1. Family history of the child with cancer: 
• ≥ 2 malignancies in childhood (individuals with multiple primary tumors) 
• A first degree relative (parent or sibling) with cancer < 50 years of age 
• ≥ 2 second degree relatives with cancer < 50 years of age on the same side of the 
family 
• Several affected generations in the same bloodline 
• Unusual tumors 
• Clustering of cancer in a family 
• Parents of the child with cancer are related (i.e., consanguineous)  
 
2. A person with one of these tumors in childhood: 
• Adrenocortical carcinoma 
• Aggressive fibromatosis 
• Atypical teratoid malignant rhabdoid tumor 
• Cancers of adult age that are extremely rare in the pediatric age group (i.e., 
colorectal cancer, ovarian cancer, pheochromocytoma, basal cell carcinoma) 
• Cerebellar gangliocytoma 
• Choroid plexus carcinoma 
• Desmoid tumor 




• Hepatocellular carcinoma 
• Juvenile myelomonocytic leukemia 
• Low hypodiploid acute lymphoblastic leukemia 
• Malignant melanoma  
• Malignant peripheral nerve sheath tumor 
• Malignant Schwannoma 
• Medullary thyroid carcinoma 
• Medulloblastoma 
• Meningioma 
• Myelodysplastic syndrome 
• Nephroblastoma (Wilms tumor) 
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• Optic pathway/optic nerve glioma 
• Ovarian Sertoli-Leydig cell tumor 
• Pheochromocytoma 
• Pineoblastoma 
• Pituitary adenoma 
• Pituitary blastoma 
• Pleuropulmonary blastoma  
• Retinoblastoma  
• Renal carcinoma 
• Rhabdomyosarcoma 
• Skin carcinoma 
• Spinal ependymoma 
• Subependymal giant cell astrocytoma 
• Thyroid carcinoma 
• Vestibular schwannoma 
 
3. Child with two malignancies, one of those with onset < 18 years of age (unless the 2nd 
malignancy is consistent in time and/or tissue type with these expected from their treatment 
regimen).  
4. Child with one of the following inherited conditions: 
• Ataxia-Telangectasia 
• Beckwith-Wiedemann Syndrome / Isolated Hemihypertrophy 
• Bannayan-Riley-Ruvalcaba Syndrome 
• Biallelic mismatch repair gene mutations 
• Bloom syndrome 
• Carney complex 
• Constitutional mismatch repair deficiency 
• Costello Syndrome 
• Cowden Syndrome 
• Denys-Drash 
• DICER1-related Pleuropulmonary Blastoma Family Tumor and Dysplasia 
Syndrome (DICER1 syndrome) 
• Familial Adenomatous Polyposis 
• Familial paraganglioma/pheochromocytoma syndrome 
• Hereditary Leiomyomatosis and Renal Cell Cancer 
• Hereditary melanoma 
• Hereditary neuroblastoma 
• Hereditary Paraganglioma-Pheochromocytoma Syndrome 
• Hyperparathyroid-jaw tumor syndrome 
• Li-Fraumeni Syndrome 
• Lynch syndrome 
• Multiple Endocrine Neoplasia, Type 1 
• Multiple Endocrine Neoplasia, Type 2 
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• Neurofibromatosis type 1 
• Neurofibromatosis type 2 
• Nevoid Basal Cell Carcinoma (Gorlin) Syndrome 
• Nimegen breakage syndrome 
• Noonan syndrome/rasopathies  
• Peutz-Jeghers Syndrome 
• PTEN Hamartoma syndrome 
• Retinoblastoma 
• Rhabdoid Predisposition Syndrome 
• Simpson-Golabi-Behmel 
• Tuberous Sclerosis Complex 
• Von Hippel-Lindau Disease 
• WAGR (Wilms tumor syndromes) 
• Paraneoplastic syndromes with concern for occult malignancy 
 
5. A child with cancer and congenital anomalies or other specific symptoms 
 
6. A child with excessive treatment toxicity 
 
Sign  Think of  
Congenital 







Aberrant growth  Length, head circumference, birth weight, asymmetric growth  
Skin anomalies  
Aberrant pigmentation i.e. > 2 café-au-lait spots, vascular skin changes, 
hypersensitivity for sunlight, multiple benign tumors of the skin  
Hematological 
disorders  
Pancytopenia, anemia, thrombocytopenia, neutropenia  
Immune deficiency   
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Appendix B  
Table 5 County Incidence Rates (Number of Patients) 






Adams 120,134 14 - 1 
Allegheny 1,329,047 253 77 58 
Armstrong 71,860 18 2 6 
Beaver 182,307 35 7 13 
Bedford 54,422 13 - 2 
Blair 143,754 28 9 9 
Butler 220,673 37 17 10 
Cambria 151,391 29 9 7 
Clarion 44,414 6 - 3 
Clearfield 83,205 22 1 1 
Clinton 49,171 11 - 2 
Crawford 105,129 13 1 6 
Elk 33,816 10 2 1 
Erie 348,269 56 22 10 
Fayette 142,532 18 9 2 
Fulton 16,533 3 - 1 
Greene 41,872 12 3 2 
Indiana 101,082 22 6 7 
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Jefferson 52,266 4 3 7 
Lawrence 99,197 23 8 9 
McKean 48,813 13 4 3 
Mercer 130,846 18 6 8 
Mifflin 57,037 14 - 1 
Potter 19,875 3 - 1 
Somerset 76,113 18 7 4 
Venango 58,496 14 4 3 
Warren 43,534 9 2 - 
Washington 232,213 50 18 16 
Westmoreland 374,197 80 22 18 
*These data were provided by the Pennsylvania Department of health. The department specifically disclaims 





Figure 4 Age-Adjusted Incidence Rate, by County, All Cancer Sites, Pennsylvania Residents Aged 
<20 Years, Invasive, 2013-2017 
*These data were provided by the Pennsylvania Department of health. The department specifically disclaims 
responsibility for any analyses, interpretations, or conclusions. 
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Appendix C Tables 
Table 6 Chi-Squared Test for Gender of Patients in Study Populations 
 Retrospective Predisposition Clinic 
Males 106 (38%) 121 (56%) 
Females 174 (62%)   95 (44%) 
Total 280 216 
 
          A chi-squared test of independence was performed to examine the relationship between the 
two study populations and the proportion of the genders seen in the clinic. The relationship 
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